Clinical trials for neuroprotection in ALS

Area of Science:

• Neuroscience
• Pharmacology
• Genetics

Background:

• Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease with limited treatment options.
• Riluzole is the only approved therapy but offers only modest survival benefits.
• The exact pathogenic mechanisms of motor neuron degeneration in ALS remain unclear.

Purpose of the Study:

• To review recent advances in disease-modifying drug discovery for ALS.
• To explore neuroprotective strategies targeting various cellular pathways.
• To highlight novel therapeutic approaches based on emerging understanding of ALS pathogenesis.

Main Methods:

• Literature review of recent research on ALS therapeutics.
• Analysis of studies investigating neuroprotective agents.
• Examination of novel drug classes and genetic targets.

Main Results:

• Several agents targeting antiglutamatergic, antioxidant, and antiapoptotic pathways have been investigated (e.g., Talampanel, Coenzyme Q10, minocycline).
• Growth factors and novel compounds like heat-shock protein co-inducers, lithium, and rapamycin show therapeutic potential.
• Understanding mRNA processing alterations in genetic ALS forms (TDP-43, FUS-TLS) offers new therapeutic avenues.

Conclusions:

• Advances in understanding ALS pathogenesis are paving the way for more effective disease-modifying therapies.
• Multiple therapeutic strategies, including novel drug classes and genetic targets, are under investigation.
• Future ALS treatments may focus on neuroprotection, cellular stress response modulation, and addressing genetic defects.